, Clinical Research Department Centre François Baclesse, Caen, France. 4 Medical Oncology Department, Centre François Baclesse, 14076 Caen, France. 5 Neurosurgery Department, Radiation Oncology Department, issue.3, 14000.
The 2016 World Health Organization classification of tumors of the central nervous system: a summary, Acta Neuropathol (Berl), vol.131, pp.803-823, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01479018
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma, N Engl J Med, vol.352, pp.987-96, 2005. ,
Patterns of failure and comparison of different target volume delineations in patients with glioblastoma treated with conformal radiotherapy plus concomitant and adjuvant temozolomide, Radiother Oncol J Eur Soc Ther Radiol Oncol, vol.97, pp.377-81, 2010. ,
Mechanisms regulating radiosensitivity of glioma stem cells, 2017. ,
Selective inhibition of parallel DNA damage response pathways optimizes Radiosensitization of glioblastoma stem-like cells, Cancer Res, vol.75, pp.4416-4444, 2015. ,
Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the glioma outcomes project, J Neurosurg, vol.99, pp.467-73, 2003. ,
Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of three consecutive radiation therapy oncology group (RTOG) clinical trials, Int J Radiat Oncol Biol Phys, vol.26, pp.239-283, 1993. ,
A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival, J Neurosurg, vol.95, pp.190-198, 2001. ,
, ADPribose) polymerases in double-strand break repair: focus on PARP1, PARP2 and PARP3, vol.329, pp.18-25, 2014.
Phase I study of the poly (ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors, Clin Cancer Res Off J Am Assoc Cancer Res, vol.14, pp.7917-7940, 2008. ,
ADP-ribose)-polymerase inhibitors as radiosensitizers: a systematic review of pre-clinical and clinical human studies, Oncotarget, vol.8, pp.69105-69129, 2017. ,
URL : https://hal.archives-ouvertes.fr/cea-01938036
Specific killing of BRCA2-deficient tumours with inhibitors of poly (ADPribose) polymerase, Nature, vol.434, pp.913-920, 2005. ,
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy, Nature, vol.434, pp.917-938, 2005. ,
Replication-dependent radiosensitization of human glioma cells by inhibition of poly (ADP-ribose) polymerase: mechanisms and therapeutic potential, Int J Radiat Oncol Biol Phys, vol.72, pp.1188-97, 2008. ,
, Phase I adult brain tumor consortium (ABTC) trial of ABT-888 (veliparib), temozolomide (TMZ), and radiotherapy (RT) for newly diagnosed glioblastoma multiforme (GBM) including pharmacokinetic (PK) data. | 2013 ASCO Annual Meeting | Virtual Meeting | Meeting Library, 2017.
Radiosensitization effect of Talazoparib, a Parp inhibitor, on glioblastoma Lesueur et al. BMC Cancer (2019) 19:198 stem cells exposed to low and high linear energy transfer radiation, Sci Rep, vol.8, p.3664, 2018. ,
Results of the OPARATIC trial: a phase I dose escalation study of olaparib in combination with temozolomide (TMZ) in patients with relapsed glioblastoma (GBM), J Clin Oncol, vol.35, p.2022, 2017. ,
Phase I clinical trials evaluating olaparib in combination with radiotherapy (RT) and/or temozolomide (TMZ) in glioblastoma patients: results of OPARATIC and PARADIGM phase I and early results of PARADIGM-2, J Clin Oncol, vol.36, 2018. ,
Design of Phase II cancer trials evaluating survival probabilities, BMC Med Res Methodol, vol.3, p.6, 2003. ,
Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide, J Clin Oncol Off J Am Soc Clin Oncol, vol.20, pp.1375-82, 2002. ,
Time-to-event continual reassessment method incorporating treatment cycle information with application to an oncology phase I trial, Biom J Biom Z, vol.56, pp.933-979, 2014. ,
Using the time-to-event continual reassessment method in the presence of partial orders, Stat Med, vol.32, pp.131-172, 2013. ,
Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group, J Clin Oncol Off J Am Soc Clin Oncol, vol.28, pp.1963-72, 2010. ,